See more : ATS Automation Tooling Systems Inc. (ATA.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Ultragenyx Pharmaceutical Inc. (RARE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ultragenyx Pharmaceutical Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Ennogie Solar Group A/S (ESG.CO) Income Statement Analysis – Financial Results
- Protean Energy Limited (POW.AX) Income Statement Analysis – Financial Results
- Reliance Naval and Engineering Limited (RNAVAL.NS) Income Statement Analysis – Financial Results
- BBX Capital, Inc. (BBXIB) Income Statement Analysis – Financial Results
- The ONE Group Hospitality, Inc. (STKS) Income Statement Analysis – Financial Results
Ultragenyx Pharmaceutical Inc. (RARE)
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 434.25M | 363.33M | 351.41M | 271.03M | 103.71M | 51.50M | 2.61M | 133.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 45.21M | 28.32M | 16.01M | 6.13M | 9.01M | 1.15M | 1.00K | 183.20M | 1.38M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 389.04M | 335.01M | 335.40M | 264.90M | 94.71M | 50.35M | 2.61M | -183.07M | -1.38M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 89.59% | 92.21% | 95.44% | 97.74% | 91.31% | 97.77% | 99.96% | -137,647.37% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 648.45M | 705.79M | 497.15M | 412.08M | 357.36M | 294.00M | 231.64M | 183.20M | 114.74M | 45.97M | 27.83M | 12.64M | 4.72M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 127.72M | 99.91M | 64.94M | 33.00M | 10.81M | 4.45M | 3.34M | 1.84M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 309.80M | 278.14M | 219.98M | 182.93M | 161.52M | 127.72M | 99.91M | 64.94M | 33.00M | 10.81M | 4.45M | 3.34M | 1.84M |
| Other Expenses | 0.00 | 9.51M | 241.00K | 7.65M | 12.45M | 3.95M | 10.60M | 2.17M | -200.00K | -3.02M | -3.01M | -350.00K | -22.00K |
| Operating Expenses | 958.25M | 983.93M | 717.14M | 595.02M | 518.88M | 421.72M | 331.55M | 248.14M | 147.74M | 56.78M | 32.28M | 15.99M | 6.56M |
| Cost & Expenses | 1.00B | 1.01B | 733.14M | 601.15M | 527.89M | 422.87M | 331.55M | 248.14M | 147.74M | 56.78M | 32.28M | 15.99M | 6.56M |
| Interest Income | 26.69M | 11.07M | 1.93M | 7.04M | 13.24M | 9.54M | 4.07M | 3.79M | 2.32M | 608.00K | 216.00K | 1.00K | 4.00K |
| Interest Expense | 66.00M | 43.02M | 29.42M | 33.29M | 1.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 270.00K |
| Depreciation & Amortization | 26.01M | 18.20M | 13.24M | 12.26M | 8.54M | 19.54M | 5.83M | 3.42M | 1.38M | 684.00K | 444.00K | 313.00K | 34.00K |
| EBITDA | -516.45M | -640.51M | -410.32M | -139.81M | -389.77M | -177.56M | -312.51M | -244.58M | -146.35M | -56.09M | -34.63M | -16.02M | -6.55M |
| EBITDA Ratio | -118.93% | -175.99% | -108.56% | -118.98% | -396.98% | -1,051.94% | -12,593.49% | -186,471.43% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -569.21M | -648.92M | -381.74M | -330.12M | -424.17M | -371.37M | -328.94M | -248.01M | -147.74M | -56.78M | -32.28M | -15.99M | -6.56M |
| Operating Income Ratio | -131.08% | -178.60% | -108.63% | -121.80% | -408.98% | -721.18% | -12,593.49% | -186,471.43% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -39.26M | -52.81M | -71.24M | 144.76M | 24.73M | 174.28M | 10.60M | 2.17M | 2.12M | -3.02M | -2.79M | -349.00K | -288.00K |
| Income Before Tax | -608.46M | -701.73M | -452.98M | -185.36M | -399.44M | -197.10M | -318.34M | -245.84M | -145.62M | -59.80M | -35.07M | -16.33M | -6.85M |
| Income Before Tax Ratio | -140.12% | -193.14% | -128.91% | -68.39% | -385.14% | -382.75% | -12,187.52% | -184,841.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.83M | 5.70M | 1.04M | 1.21M | 3.28M | 514.00K | -16.20M | 35.00K | -2.32M | -684.00K | -3.01M | -350.00K | 248.00K |
| Net Income | -606.64M | -707.42M | -454.03M | -186.57M | -402.73M | -197.61M | -302.14M | -245.87M | -145.62M | -59.80M | -35.07M | -16.33M | -6.85M |
| Net Income Ratio | -139.70% | -194.71% | -129.20% | -68.84% | -388.31% | -383.75% | -11,567.34% | -184,867.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -8.25 | -10.12 | -6.70 | -3.07 | -7.12 | -3.97 | -7.12 | -6.21 | -3.96 | -2.08 | -1.21 | -0.71 | -0.30 |
| EPS Diluted | -8.25 | -10.12 | -6.70 | -3.07 | -7.12 | -3.97 | -7.12 | -6.21 | -3.96 | -2.08 | -1.21 | -0.71 | -0.30 |
| Weighted Avg Shares Out | 73.54M | 69.91M | 67.80M | 60.85M | 56.58M | 49.78M | 42.45M | 39.59M | 36.78M | 28.76M | 29.06M | 23.06M | 23.06M |
| Weighted Avg Shares Out (Dil) | 73.54M | 69.91M | 67.80M | 60.85M | 56.58M | 49.78M | 42.45M | 39.59M | 36.78M | 28.76M | 29.06M | 23.06M | 23.06M |
Ultragenyx to Host Conference Call for Third Quarter 2023 Financial Results and Corporate Update
Will Ultragenyx (RARE) Report Negative Q3 Earnings? What You Should Know
Ultragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Ultragenyx Announces Proposed Public Offering of Common Stock
Ultragenyx (RARE) Surges 10.3%: Is This an Indication of Further Gains?
Ultragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (OI), Angelman Syndrome (AS) and Wilson Disease
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Source: https://incomestatements.info
Category: Stock Reports